Seagen Inc. (SGEN)
After hours:
Chart Events
Performance Outlook
| Previous Close | 176.94 |
| Open | 174.82 |
| Bid | 174.82 x 1000 |
| Ask | 188.78 x 1000 |
| Day's Range | 174.52 - 180.49 |
| 52 Week Range | 105.43 - 192.79 |
| Volume | |
| Avg. Volume | 1,387,450 |
| Market Cap | 32.934B |
| Beta (5Y Monthly) | 0.82 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.84 |
| Earnings Date | Apr 27, 2022 - May 02, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 159.88 |
- Barrons.com
Biotech Stocks Finally Rose in June. What Does It Mean?
The (ticker: XBI), which tracks small- and mid-cap biotech stocks, fell 33.7% in the first half of the year, which ended on Thursday. The (IBB), which tracks larger biotech names, fell 22.8%. In a note out early Friday, analysts with Cowen biotechnology team noted that June represented the XBI’s first positive month since last August.
- Zacks
Here's Why Seattle Genetics (SGEN) is a Great Momentum Stock to Buy
Does Seattle Genetics (SGEN) have what it takes to be a top stock pick for momentum investors? Let's find out.
- Benzinga
SVB Leerink's Pro-forma Analysis Of Speculated Merck/Seagen Deal - What Investors Need To Know
SVB Securities conducted a pro-forma analysis of the financial impact to Merck & Co Inc (NYSE: MRK) from a potential acquisition of Seagen Inc (NASDAQ: SGEN). The analysts refrain from commenting on the probability of the deal happening. The analysis suggests that the short-term impact on EPS from the potential acquisition will likely be meaningfully dilutive. Related: Merck Shows Takeover Interest In Seagen: WSJ. According to SVB, the deal decreases forecasted GAAP EPS by -12%, -7%, and -2% in
